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Abstract
Immunity to Plasmodium falciparum (Pf) malaria is only acquired after years of repeated infections and wanes rapidly
without ongoing parasite exposure. Antibodies are central to malaria immunity, yet little is known about the B-cell biology
that underlies the inefficient acquisition of Pf-specific humoral immunity. This year-long prospective study in Mali of 185
individuals aged 2 to 25 years shows that Pf-specific memory B-cells and antibodies are acquired gradually in a stepwise
fashion over years of repeated Pf exposure. Both Pf-specific memory B cells and antibody titers increased after acute malaria
and then, after six months of decreased Pf exposure, contracted to a point slightly higher than pre-infection levels. This
inefficient, stepwise expansion of both the Pf-specific memory B-cell and long-lived antibody compartments depends on Pf
exposure rather than age, based on the comparator response to tetanus vaccination that was efficient and stable. These
observations lend new insights into the cellular basis of the delayed acquisition of malaria immunity.
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Introduction
To date, most successful vaccines have targeted pathogens that
induce long-lived protective antibodies after a single infection,
such as the viruses that cause smallpox, measles and yellow fever
[1]. It has proved more difficult to develop highly effective
vaccines against pathogens that do not induce sterile immunity
such as the human immunodeficiency virus type-1 (HIV-1),
Mycobacterium tuberculosis (Mtb), and Plasmodium falciparum malaria
[2]. However, unlike HIV-1 and Mtb, clinical immunity to
malaria can be acquired, but only after years of repeated Pf
infections [3]. Passive transfer studies indicate that antibodies
ultimately play a key role in protection from malaria [4], yet
several studies show that antibodies to Pf antigens are inefficiently
generated and rapidly lost in the absence of ongoing exposure to
the parasite (reviewed in [5]). Elucidating the cellular basis of the
inefficient acquisition of malaria immunity may ultimately prove
critical to the design of an effective malaria vaccine.
Despite the key role that antibodies play in protection from a
variety of infectious diseases, remarkably little is known about the
cellular basis of acquiring humoral immunity in response to natural
infections in humans. This gap in our knowledge is due in large part
to the difficulty in studying natural infections in humans when we
cannot predict who within a population will be infected with a given
pathogen at a given time. Thus, our current understanding of the
acquisition of immunity is largely derived from animal models and
studies of humans after vaccination. These studies have established
that long-lived, antibody-based immunity requires the generation and
maintenance of memory B cells (MBCs) and long-lived plasma cells
(LLPCs) (reviewed in [6,7]). This process begins when naı ¨ve B cells
bind antigen near the interface of B and T cell areas of secondary
lymphoid organs. Several studies suggest that high-affinity binding
drives naı ¨ve B cells to differentiate into short-lived, isotyped switched
plasma cells (PCs) within the extra-follicular region which contributes
to the initial control of infection. In contrast, lower affinity binding
selects for entry of naı ¨ve B cells into follicles where germinal centers
are formed. After a period of 7–10 days, through the CD4
+ T-cell
dependent process of somatic hypermutation, the germinal center
reaction yields MBCs and LLPCs of higher affinity than the initial
wave of short-lived plasma cells (SLPCs). MBCs recirculate and
mediate recall responses after re-exposure to their cognate antigen by
rapidly expanding and differentiating into PCs, whereas LLPCs
r e s i d i n gi nt h eb o n em a r r o wc o n s t itutively secrete antibody and
provide a critical first line of defense against re-infection.
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over the human life-span remains an open question. In one
model, LLPCs survive indefinitely in the bone marrow and
independently maintain steady-state antibody levels [8]. Alter-
native models predict that PCs are replenished by MBCs that
proliferate and differentiate in response to persistent [9] or
intermittent exposure to antigen, and/or through non-specific
by-stander activation (e.g. cytokines or TLR ligands) [10].
Unlike PCs, which are terminally-differentiated, MBCs may be
maintained through homeostatic proliferation [11], possibly
through exposure to polyclonal stimuli [10]. To address
fundamental questions related to the generation and mainte-
nance of MBCs and Abs specific for Pf malaria in children in
malaria endemic areas, we conducted a year-long prospective
study in a rural village of Mali that experiences an intense,
sharply-demarcated six-month malaria season annually. We
determined whether Pf infection generates MBCs specific for Pf
blood stage antigens, and if so, whether they accumulate with
age and cumulative Pf exposure, and also whether their
frequency correlates with protection from malaria. In addition,
we determined whether acute, symptomatic Pf infection resulted
in an increase in the number of Pf-specific MBCs and the levels
of specific antibodies, and if so, whether this increase remained
stable over a six-month period of markedly reduced Pf
transmission. By taking advantage of the tetanus immunization
schedule in Mali in which infants and women of child-bearing
age are vaccinated, we compared the relative efficiencies of the
acquisition of tetanus toxoid (TT)- and Pf-specific MBCs and
Ab, and also tested three hypotheses: 1) that growth of the MBC
compartment depends on immunological experience rather than
age, 2) that Pf infection induces non-specific activation of
bystander B cells [12,13], and 3) that polyclonal activation
during heterologous immune responses is a general mechanism
for maintaining MBCs and LLPCs [10].
Results
Malaria immunity is acquired gradually despite intense
exposure to the Pf parasite
In May 2006 we initiated an observational cohort study in Mali
to investigate the mechanisms underlying naturally-acquired
malaria immunity. A detailed description of the study site and
cohort has been reported elsewhere [14]. The study population
was an age-stratified, random sample representing 15% of all
individuals living in a small, rural, well-circumscribed, non-
migratory community where antimalarial drugs were provided
exclusively by the study investigators. During a two-week period
one month prior to the abrupt onset of the six-month malaria
season, we enrolled 225 individuals in four age groups: 2–4 years
(n=73), 5–7 years (n=52), 8–10 years (n=51), and 18–25 years
(n=49). Attendance at scheduled follow-up visits was .99% for
children (2–10 years) and 82% for adults (18–25 years) during the
one-year study period indicating a high degree of study awareness
and participation. For the MBC analysis reported here, a subset of
185 individuals was randomly selected within each of the four age
categories. All subsequent data and analysis refer to these 185
individuals. The baseline demographic and clinical characteristics
of this subset are shown in Table 1, according to age group. As
previously reported [14], only three of the characteristics shown in
Table 1 were associated with decreased malaria risk in
multivariate analysis—increasing age, sickle cell trait (HbAS),
and asymptomatic Pf parasitemia at study enrollment. During the
one-year study period there were 380 unscheduled clinic visits,
during which 219 cases of malaria were diagnosed, five of which
met the WHO criteria for severe malaria [15]. Malaria episodes
were defined as an axillary temperature $37.5uC, Pf asexual
parasitemia $5000 parasites/mL, and a non-focal physical exam
by the study physician. As expected in this region of Mali, all
malaria cases were confined to a six-month period that began in
July, peaked in October, and ended by January (Fig. 1A). The
incidence of malaria and the proportion of individuals experienc-
ing at least one malaria episode decreased with age, whereas the
time to the first malaria episode increased with age (Table 2 and
Fig. 1B). Thus, despite intense annual Pf transmission at this study
site, malaria immunity is acquired slowly.
Analysis of Pf-specific and TT-specific MBCs and Abs in Pf-
uninfected children and adults before the malaria season
We first established baseline levels of IgG
+ AMA1-, MSP1- and
TT-specific MBCs and Abs in Pf-uninfected, healthy children and
adults in May just before the malaria season, a point at which
there had been little to no Pf transmission for five months. For this
analysis we excluded individuals with asymptomatic Pf parasitemia
(8.7% of total cohort; Table 1), because they showed a decreased
risk of malaria and tended toward higher frequencies of AMA1-
and MSP1-specific MBCs and levels of Ab (data not shown).
We focused our analyses on MBCs and Abs specific for Pf
blood-stage antigens because humoral responses are known to be
critical to blood-stage immunity [4]. We examined the response to
two blood stage proteins, Apical Membrane Antigen 1 (AMA1)
and Merozoite Surface Protein 1 (MSP1), because we had
previously studied the MBC and Ab responses to these antigens
in vaccine trials of Pf-naı ¨ve individuals [16]. This afforded the
opportunity to compare the acquisition of B cell memory to the
same antigens after vaccination versus natural Pf infection. We
express MBC data as ‘MBCs per 10
6 PBMCs’, where ‘MBCs’
refers to the number of antibody secreting cells derived from
MBCs during the six-day culture, and ‘10
6 PBMCs’ refers to the
number of PBMCs after culture. In the present study, the mean
Author Summary
Plasmodium falciparum (Pf) is a mosquito-borne parasite
that causes over 500 million cases of malaria annually, one
million of which result in death, primarily among African
children. The development of an effective malaria vaccine
would be a critical step toward the control and eventual
elimination of this disease. To date, most licensed vaccines
are for pathogens that induce long-lived protective
antibodies after a single infection. In contrast, immunity
to malaria is only acquired after repeated infections.
Antibodies play a key role in protection from malaria, yet
several studies indicate that antibodies against some Pf
proteins are generated inefficiently and lost rapidly. The
cells that are responsible for the maintenance of antibod-
ies over the human lifespan are memory B-cells and long-
lived plasma cells. To determine how these cells are
generated and maintained in response to Pf infection, we
conducted a year-long study in an area of Mali that
experiences a six-month malaria season. We found
memory B-cells and long-lived antibodies specific for the
parasite were generated in a gradual, step-wise fashion
over years despite intense Pf exposure. This contrasts
sharply with the efficient response to tetanus vaccination
in the same population. This study lends new insights into
the delayed acquisition of malaria immunity. Future
studies of the cellular and molecular basis of these
observations could open the door to strategies for the
development of a highly effective malaria vaccine.
Memory B Cell Response to P. falciparum Malaria
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6 PBMCs increased with
age (Fig. 2A; 2–4 yr: 1.2 [95% CI: 0.45–1.9]; 5–7 yr: 5.0 [95% CI:
20.2–10.1]; 8–10 yr: 8.9 [95% CI: 4.9–12.9]; 18–25 yr: 37.8
[95% CI: 10.4–65.3]; P,0.001), as did the proportion of
individuals with detectable AMA1-specific MBCs (2–4 yr: 8.1%;
5–7 yr: 30.8%; 8–10 yr: 50.0%; 18–25 yr: 54.8%; P,0.001).
Similarly, AMA1-specific Ab levels and the proportion of
individuals seropositive for AMA1-specific Abs increased with
age (Fig. 2A; P,0.001 for both comparisons). There was a positive
correlation between the frequency of AMA1-specific MBCs and
Ab levels (Spearman’s correlation coefficient=0.35; P=0.005;
Fig. S1).
We observed a similar age-associated increase in the frequency
of MSP1-specific MBCs, although the overall frequency was lower
than that for AMA1-specific MBCs (Fig. 2B; 2–4 yr: 1.2 [95% CI:
0.55–1.9]; 5–7 yr: 3.2 [95% CI: 1.2–5.2]; 8–10 yr: 5.9 [95% CI:
2.9–9.0]; 18–25 yr: 10.3 [95% CI: 6.3–14.3]; P,0.001). Likewise,
the proportion of individuals who had detectable MSP1-specific
MBCs (2–4 yr: 9.1%; 5–7 yr: 27.8%; 8–10 yr: 34.3%; 18–25 yr:
47.6%; P=0.001) was similar to that for AMA1. MSP1-specific
Ab levels and the proportion of individuals seropositive for MSP1-
specific Abs also increased gradually with age (Fig. 2B; P,0.001
for both comparisons). There was a positive correlation between
the frequency of MSP1-specific MBCs and Ab levels (Spearman’s
correlation coefficient=0.34; P=0.004; Fig. S1). Remarkably,
despite exposure to 50–60 infective mosquito bites per month at
the peak of each malaria season in this area [17], only
approximately half of adults had detectable MBCs specific for
AMA1 and MSP1, even though most had detectable AMA1- and
MSP1-specific antibodies. Of the 72 individuals without detectable
AMA1-specific MBCs before the malaria season, 64 (88.9% [95%
CI 79.3–95.1]) did not have detectable MSP1-specific MBCs,
suggesting that failure to generate MBCs to one Pf antigen is
associated with failure to generate MBCs to other Pf antigens.
To understand if the expansion of Pf-specific MBCs with age
was driven by repeated exposure to Pf antigens or simply a
function of age, we determined the frequency of MBCs specific for
an unrelated antigen, tetanus toxoid (TT), with age. In Mali, a
single TT vaccine is administered to infants less than six months of
age and a second TT vaccine is administered to females around 15
years of age to prevent neonatal tetanus. Thus, we measured TT-
specific antibody and MBC responses at least 18 months after TT
vaccination, a point at which the TT-specific response is likely to
be at steady state. In contrast to what was observed for AMA1-
and MSP1-specific MBCs, the frequency of TT-specific MBCs
among males did not change significantly from age 2 to 25 years
(Fig. 2C) (2–4 yrs: 10.8 [95% CI 27.4–29.0], 5–7 yrs: 7.3 [95%
CI 0.7–13.9], 8–10 yrs: 8.0 [95% CI 3.1–12.8], 18–25 yrs: 4.7
[95% CI 1.4–8.1]; P=0.80). Similarly, the proportion of male
adults who were positive for TT-specific MBCs did not differ
significantly from male children (2–4 yrs: 25.0%, 5–7 yrs: 33.3%,
8–10 yrs: 40.9%, 18–25 yrs 28.6%; P=0.80). The slightly higher
frequency of TT-specific MBCs in male versus female children
was not statistically significant. However, the frequency of TT-
specific MBCs was significantly higher in female adults compared
to female children (Fig. 2C; mean frequency of TT-specific MBCs
per million PBMC by age group (2–4 yrs: 2.9 [95% CI 1.1–4.7],
5–7 yrs: 3.2 [95% CI 0.2–6.1], 8–10 yrs: 3.4 [95% CI 1.1–5.7],
18–25 yrs: 58.7 [95% CI 34.2–83.3]; P,0.001) presumably the
result of booster vaccination. Likewise, the proportion of female
adults who were positive for TT-specific MBCs was significantly
higher as compared to female children (2–4 yrs: 28.1%, 5–7 yrs:
25.0%, 8–10 yrs: 27.3%, 18–25 yrs 88.0%; P,0.001). For both
females and males, TT-specific Ab levels mirrored MBC
frequencies (Fig. 2C)—clearly increasing from female children to
female adults (P,0.001), while not changing significantly by age in
males (P=0.44). Overall, TT-specific Ab levels and MBC
frequencies correlated (Spearman’s correlation coefficient=0.48;
Table 1. Baseline characteristics of the study cohort by age group.
Age group, years All (n=185)
2–4 (n=59) 5–7 (n=37) 8–10 (n=42) 18–25 (n=47)
Gender, % female (no.) 66.1 (39) 48.7 (18) 33.3 (14) 61.7 (29) 54.1 (100)
Ethnicity, % (no.)
Bambara 62.7 (37) 51.4 (19) 54.8 (23) 66.0 (31) 59.5 (110)
Sarakole 32.2 (19) 43.2 (16) 35.7 (15) 27.7 (13) 34.1 (63)
Fulani 3.4 (2) 5.4 (2) 7.1 (3) 4.3 (2) 4.9 (9)
Malinke 1.7 (1) 0.0 (0) 2.4 (1) 2.1 (1) 1.6 (3)
Hemoglobin AS, % (no.)
a – 13.6 (8) 8.1 (3) 7.1 (3) 10.6 (5) 10.3 (19)
P. falciparum smear positive at enrollment, % (no.)
b – 6.8 (4) 10.8 (4) 11.9 (5) 6.4 (3) 8.7 (16)
Parasitemia if smear positive at enrollment,
parasites/microliter [geometric mean (95% CI)]
1438
(159–12973)
3616
(1500–8715)
415
(134–1287)
953
(39–23381)
1137
(579–2232)
GI helminth, % positive at enrollment (no.)
c – 14.6 (8) 8.3 (3) 11.8 (4) 0 (0) 9.7 (15)
Urine schistosomiasis, % positive at enrollment (no.)
d – 0 (0) 0 (0) 5.3 (2) 29.0 (9) 7.4 (11)
Distance lived from clinic, meters (mean 6SD) 395 (6116) 408 (6140) 365 (683) 359 (691) 382 (6110)
Bed net use, % (no.)
e – 27.3 (15) 41.2 (14) 17.1 (7) 39.5 (15) 30.4 (51)
a –Data available for 177 subjects.
b –All subjects were asymptomatic at enrollment.
c –Data available for 154 subjects; GI=gastrointestinal.
d –Data available for 148 subjects.
e –Nightly bednet use self-reported at the end of the malaria season.
doi:10.1371/journal.ppat.1000912.t001
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increased with age while TT-specific MBCs in individuals who
received no booster vaccine did not increase and tended to
decrease slightly with age indicates that the increase in Pf-specific
MBCs is driven by repeated antigen exposure and is not simply a
function of age. Of note, the size of the total IgG
+ MBC
compartment, as reflected in the peripheral blood, increased with
age (Fig. 3; P,0.001), consistent with the maturation of the total
MBC compartment with immunological experience.
Longitudinal analysis of the Pf- and TT-specific MBC and
Ab responses two weeks after acute malaria and after a
prolonged period of decreased Pf exposure
To assess the Pf-specific MBC and Ab responses to acute
malaria, and to determine the stability of this response during a
period of little to no Pf transmission, we measured the frequencies
of MBCs and Ab levels specific for AMA1 and MSP1 14 days after
the first episode of malaria (convalescence), and in a cross-sectional
survey at the end of the following dry season (month 12), and
compared these frequencies to the pre-malaria season baseline
(month 0; as detailed above). Malaria episodes were defined as an
axillary temperature $37.5uC, Pf asexual parasitemia $5000
parasites/mL, and a non-focal physical exam by the study
physician. Because few adults experienced malaria (Table 2), this
analysis only included children aged 2–10 years (see Fig. 4 for
sample sizes at each time point). The mean frequency of AMA1-
specific MBCs in children aged 2–10 years increased from month
0 to convalescence (Fig. 4A; month 0: 4.7 [95% CI: 2.8–6.6];
convalescence: 13.4 [95% CI: 2.7–24.1; P=0.006] and then
decreased from convalescence to month 12 (Fig. 4A; month 12: 5.9
[95% CI: 2.4–9.4]; P=0.93 versus convalescence) to a point just
above the frequency at month 0 (Fig. 4A; P=0.021, month 0 vs.
month 12). Likewise, the level of AMA1-specific Ab increased
from month 0 to convalescence (Fig. 4A; month 0: 422.8 [95% CI:
228.7–617.0]; convalescence: 797.2 [95% CI: 460.0–1134.7;
P,0.001], and then decreased from convalescence to month 12
(Fig. 4A; month 12: 535.5 [95% CI: 283.8–787.2]; P,0.001
versus convalescence], to a point just above month 0 levels (Fig. 4A;
P=0.040, month 0 vs. month 12).
The MSP1-specific MBC and Ab responses followed a similar
pattern. The mean frequency of MSP1-specific MBCs in children
aged 2–10 years increased from month 0 to convalescence (Fig. 4B;
month 0: 3.3 [95% CI: 2.0–4.6]; convalescence: 4.8 [95% CI: 2.9–
6.8; P=0.002] and then decreased from convalescence to month
12 (Fig. 4B; month 12: 4.5 [95% CI: 2.4–6.6]; P=0.71 versus
convalescence) to a point just above the frequency at month 0
Table 2. Malaria clinical outcomes by age group.
Age group, years All (n=185)
2–4 (n=59) 5–7 (n=37) 8–10 (n=42) 18–25 (n=47)
Malaria incidence, mean (6SD)
a –1 . 8 6 ( 61.28) 1.81 (61.17) 0.95 (61.08) 0.09 (60.28) 1.19 (61.27)
Severe malaria incidence, no.
b – 4 1005
At least one malaria episode, % (no.) 83.1 (49) 81.1 (30) 57.1 (24) 8.5 (4) 57.8 (107)
Time to first malaria episode, days (median)
c – 101 121 124 153 118
Parasitemia at first malaria episode,
parasites/microliter [geometric mean (95% CI)]
39084
(30579–49954)
26417
(19440–35896)
20561
(15683–26956)
8816
(4082–19037)
28678
(24334 –33799)
a –Malaria episode defined as T$37.5uC, asexual parasitemia $5000/microliter, and non-focal physical examination.
b –WHO definition of severe malaria.
c –Days since study enrollment.
doi:10.1371/journal.ppat.1000912.t002
Figure 1. Malaria immunity is acquired gradually despite
intense annual exposure to the Pf parasite. (A) Number of malaria
episodes per day during the study period. Over a one-year surveillance
period 185 individuals experienced 219 malaria episodes during a
sharply-demarcated six-month malaria season. Malaria episodes were
defined as fever $37.5uC and Pf asexual parasitemia $5000/mL blood.
To track the B-cell response to acute malaria, and after a period of
reduced Pf exposure, PBMCs and plasma were collected at points
indicated by the arrows: before the malaria season, two weeks after the
first malaria episode (arrow with asterisk indicates the mean time to first
malaria episode, 132 days from enrollment), and six months after the
end of the malaria season. (B) Kaplan-Meier estimates of the cumulative
probability of malaria over the study period, according to age category.
The number of individuals at risk over the study period is shown below
the graph. The P value was obtained using the log rank test.
doi:10.1371/journal.ppat.1000912.g001
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MSP1-specific Ab increased from month 0 to convalescence
(Fig. 4B; month 0: 14.6 [95% CI: 10.5–18.6]; convalescence:
302.6 [95% CI: 111.7–493.4; P,0.001], and then decreased from
convalescence to month 12 (Fig. 4B; month 12: 31.1 [95% CI:
5.5–56.6]; P,0.001 versus convalescence], to a point just above
month 0 levels (Fig. 4B; P=0.052, month 0 vs. month 12).
Figure 2. The Pf-specific MBC and long-lived antibody com-
partments expand gradually with age. Shown are the MBC
frequencies (bars, left axis) and antibody levels (lines, right axis) specific
for AMA1 (A) and MSP1 (B) by age category; and TT (C) by age category
and gender; before the malaria season in Pf-uninfected individuals. The
frequency of AMA1- and MSP1-specific MBCs increased with age
(P,0.001 for both trends), as did the level of AMA1- and MSP1-specific
antibodies (P,0.001 for both trends). There were no significant
differences by gender for the AMA1- and MSP1-specific responses
(not shown). To determine if the expansion of Pf-specific MBCs with age
was driven by exposure to antigen or simply a function of age, we
measured the TT-specific MBC and antibody response with age. In Mali,
infants are vaccinated with TT, and females receive a TT booster around
the age of 15 years to prevent neonatal tetanus. In contrast to AMA1
and MSP1, the frequency of TT-specific MBCs and the level of TT-specific
antibodies for males did not change significantly from age 2 to 25 years
(P=0.80 and P=0.44, respectively). However, the frequency of TT-
specific MBCs and the level of TT-specific antibodies was higher in
female adults compared to female children (P,0.001 for both
comparisons). MBC frequencies were determined by ELISPOT and are
expressed per million PBMC. The number of individual samples assayed
and the percent of individual samples that exceeded the limit of
detection (i.e. those considered positive) is indicated below the graph.
The discrepancy in the sample size for ELISA data among 2–4 year olds
is due to technical error during the performance of the ELISA. P values
were obtained by the Kruskal-Wallis test. Data are shown as mean 6
s.e.m.
doi:10.1371/journal.ppat.1000912.g002
Figure 3. The size of total IgG
+ MBC compartment expands
gradually with age. The frequency of IgG
+ MBCs per million PBMCs
measured before the malaria season increased with age (P,0.001). The
number of individuals in each age category is indicated. The P value
was obtained by the Kruskal-Wallis test. Data are shown as mean 6
s.e.m.
doi:10.1371/journal.ppat.1000912.g003
Memory B Cell Response to P. falciparum Malaria
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‘bystander’ MBCs, we compared the frequencies of TT-specific
MBCs and Ab levels before the malaria season (month 0) to that
14 days after acute malaria (convalescence). We observed a small,
but statistically significant increase in the frequency of TT-
specific MBCs from month 0 to convalescence (Fig. 4C; month
zero: 7.1 [95% CI: 3.1–11.2]; convalescence: 8.4 [95% CI: 5.0–
11.8; P=0.012) that did not change significantly at month 12
(month 12: 9.1 [95% CI: 3.2–15.4]; P=0.974 versus convales-
cence]. In contrast, TT-specific Ab levels decreased slightly from
month 0 to convalescence, and again from convalescence to
month 12, although neither decline was statistically significant
(Fig. 4C; month 0: 0.58 [95% CI: 0.5–0.7]; convalescence: 0.57
[95% CI: 0.5–0.7; P=0.063]; month 12: 0.54 [95% CI: 0.4–0.6];
P=0.525 versus convalescence). Collectively these results indicate
that malaria infection results in an increase in the frequencies of
both Pf-specific, and bystander MBCs. However, malaria
selectively induces Pf-specific Ab production but does not appear
to drive the differentiation of bystander naı ¨ve and memory B cells
into PCs.
B cell subsets in Pf-uninfected children and adults before
the malaria season
By FACS we determined the proportion of B cell subsets in
individuals (2–4 yrs [n=38], 5–7 yrs [n=21], 8–10 yrs [n=23],
18–25 yrs [n=27]) before the malaria season (Fig. 5A). With
increasing age, and as a percentage of total CD19
+ B cells we
observed a decrease in immature B cells (CD19
+ CD10
+;
P,0.001) and naı ¨ve B cells (CD19
+ CD27
2 CD21
+ CD10
2;
P=0.047) and an increase in resting IgG
+ MBCs (CD19
+ CD27
+
CD21
+;P ,0.001) and activated IgG
+ MBCs (CD19
+ CD27
+
CD21
2 CD20
+ CD10
2;P ,0.001). The increase with age of
classical MBCs is consistent with the increase in total IgG
+ MBCs
we observed using the MBC ELISPOT assay (Fig 3).
In a subset of 87 individuals from this same study cohort, we
previously reported that Pf exposure is associated with an
expanded subset of ‘atypical’ MBCs that express FCRL4 and
are hyporesponsive to in vitro stimuli [18], similar to the ‘exhausted’
MBCs described in viremic, HIV-infected individuals [19].
Atypical MBCs are defined as CD19
+ CD27
2 CD21
2 CD20
+
CD10
2 and typically represents ,4% of circulating CD19
+ B cells
in healthy U.S. adults [19]. Here, analyzing a larger number of
individuals in the cohort, we confirmed that this subset of MBCs is
expanded in Malian children and adults compared to malaria-
naı ¨ve U.S. adults (U.S. adults: 1.4% [95% CI: 0.9–1.8]; Malian
children aged 2–10 years: 10.2% [95% CI: 8.7–11.8], P,0.001
versus U.S. adults; Malian adults aged 18–25 years: 14.8% [95%
CI: 11.0–19.1], P,0.001 versus U.S. adults). Thus, in addition to
the increase in classical MBCs, an ‘atypical’ MBC subset is
expanding with age in this study population.
Figure 4. Longitudinal analysis of the Pf- and TT-specific MBC
and antibody response. Compared to month zero, the MBC
frequencies and antibody levels specific for AMA1 (A) and MSP1 (B)
increased two weeks after the first episode of malaria and then
contracted to a point slightly higher than pre-infection levels after a six-
month period of decreased Pf exposure. Compared to month zero,
there was a small but statistically significant increase in TT-specific MBC
two weeks after the first episode of malaria (C), whereas the level of TT-
specific antibodies did not change. The number of individuals in each
age category is indicated. Only statistically significant P values are
shown. P values were obtained by the Wilcoxon matched-pairs signed-
rank test. Data are shown as mean 6 s.e.m.
doi:10.1371/journal.ppat.1000912.g004
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and after acute malaria
We investigated the impact of acute malaria on the relative
proportion of B cells in each subset in children aged 2–10 years.
Compared to the pre-malaria season baseline (month 0), there
were no significant changes in the percent of lymphocytes that
were CD19
+ 14 days after acute malaria. Within the CD19
+ B cell
population there were no significant changes in the percent of
immature B cells, naı ¨ve B cells, or resting MBCs, after acute
malaria. Moreover, there was no change in the proportions of
resting and atypical MBCs that were IgG
+. However, we observed
a decrease in the percentage of total atypical MBCs (Fig. 5B;
month 0: 10.9% [95% CI: 9.4–12.4], convalescence: 8.7% [95%
CI: 7.3–10.2]; P=0.027), and an increase in activated MBCs
following acute malaria (month 0: 1.6 [95% CI: 1.2–2.0],
convalescence: 1.9 [95% CI: 1.4–2.4]; P=0.09). Within the
activated MBC subset there was a significant increase in the
proportion that were IgG
+ (month 0: 59.0% [95% CI: 56.0–62.1],
month 12: 62.8% [95% CI: 59.2–66.3]; P,0.001). The decrease
in the proportion of atypical MBCs in the peripheral blood
suggests that this subpopulation may be trafficking out of the
circulation into tissues in response to acute malaria.
AMA1- and MSP1-specific MBC frequencies and Ab levels
and malaria risk
We determined prospectively whether AMA1- or MSP1-specific
Ab levels or MBC frequencies measured just prior to the six month
malaria season were associated with the subsequent risk of malaria.
For this analysis a malaria episode was defined as an axillary
temperature $37.5uC, Pf asexual parasitemia $5000 parasites/
mL, and a non-focal exam by the study physician. Because the
incidence of malaria was very low in adults during the study period
(Table 2), they were excluded from this analysis. Three measures
of malaria risk were analyzed: 1) whether or not malaria was
experienced, 2) the incidence of malaria, and 3) the time to the first
malaria episode. In the corresponding multivariate regression
models (logistic, Poisson, and Cox regression) which controlled for
age, sickle cell trait, and concurrent asymptomatic Pf parasitemia,
we found no correlation between malaria risk and AMA1- or
MSP1- specific Ab levels or MBC frequencies. As discussed below,
this finding was not unexpected based on the observation that the
malaria vaccine candidates AMA1 and MSP1 did not confer
protection against malaria in clinical trials [20,21].
Discussion
In this year-long prospective study of children and adults in an
area of intense, annual, sharply demarcated Pf transmission, we
show that MBCs specific for Pf can be acquired, but only gradually
in a stepwise fashion over years of repeated Pf exposure. MBCs
specific for two Pf antigens, AMA1 and MSP1, increased in
frequency in response to acute Pf infection, and then contracted
during a six-month period of decreased Pf exposure to a point
slightly above pre-infection levels. Cross-sectional analysis of
individuals aged 2–25 years just before the malaria season
indicated that this step-wise, incremental increase in Pf-specific
MBCs with each malaria season contributes to the gradual
expansion of the Pf-specific MBC compartment with cumulative Pf
exposure. By comparison, the stable frequency of TT-specific
MBCs with age after immunization in infancy indicates that
growth of antigen-specific MBC compartments does not simply
occur with age, but requires repeated antigen exposure. We do not
formally know if the gradual gain in Pf-specific MBCs is in fact due
to an increase in long-lived MBCs, or whether those MBCs
require Pf-stimulation and would be lost if Pf transmission did not
resume after the six-month dry season. In another setting, namely
in an area of Thailand with low Pf transmission, Wipasa et al. [22]
recently reported that nearly half of adults studied had acquired
long-lived Pf-specific MBCs as a result of infrequent malaria
infections. It will be of genuine interest to understand the cellular
Figure 5. Profile of B-cell subsets before the malaria season in
children and adults. (A) By flow cytometry the following B cell
subsets were quantified from samples collected before the malaria
season: immature B cells CD19
+ CD10
+, naı ¨ve B cells CD19
+ CD27
2
CD21
+ CD10
2, atypical MBCs CD19
+ CD27
2 CD21
2 CD10
2, classical
MBCs CD19
+ CD27
+ CD21
+, activated MBCs CD19
+ CD21
2 CD27
+ CD20
+,
and PCs CD19
+ CD21
2 CD20
2 CD10
2. As a percentage of CD19
+ B cells,
immature B cells (P,0.001) and naı ¨ve B cells (P=0.047) decreased with
age, while atypical MBCs (P=0.002), IgG
+ atypical MBCs (P,0.001), IgG
+
classical MBCs (P,0.001)), activated MBCs (P=0.001), IgG
+ activated
MBCs (P,0.001) and PCs (P=0.046) increased with age. P values were
obtained by the Kruskal-Wallis test. (B) As a percentage of CD19
+ B cells,
atypical MBCs decreased 14 days after acute malaria in children aged 2–
10 years compared to the percentage before the malaria season. The P
value was obtained by the Wilcoxon matched-pairs signed-rank test.
Data are shown as mean 6 s.e.m.
doi:10.1371/journal.ppat.1000912.g005
Memory B Cell Response to P. falciparum Malaria
PLoS Pathogens | www.plospathogens.org 7 May 2010 | Volume 6 | Issue 5 | e1000912and molecular mechanisms at play in the generation of MBCs
under these very different conditions of exposure of children versus
adults as these could have significance with regard to vaccine
development. Moreover, recent studies in mouse models are
revealing multiple, phenotypically and functionally distinct
populations of MBCs [23,24] and it will be of interest to further
characterize Pf-specific MBCs in different malaria endemic
settings.
The study described here provides a rare view of the acquisition
and maintenance of human B cell memory. Most prospective
studies of human B and T cell immunological memory have
evaluated responses to vaccination rather than natural infection, in
part because of the difficulty of predicting who within a population
will be infected with a given pathogen at a given time. In response
to a single vaccination, several studies have described an expansion
and contraction of vaccine-specific MBCs [25,26] and CD8
+
memory T cells [27]. In one of the few longitudinal studies of the
MBC response to natural infection, Harris et al. examined antigen-
specific MBC responses of patients presenting with acute Vibrio
cholerae infection, a pathogen that elicits long-term protective
immunity against subsequent disease [28]. In contrast to our
results, they observed that the majority of patients acquired IgA
and IgG MBCs specific for two Vibrio cholerae antigens and that
these persisted up to one year after infection.
Whereas MBCs mediate recall responses to reinfection by
rapidly expanding and differentiating into PCs, LLPCs residing in
the bone marrow constitutively secrete antibody in the absence of
antigen and thus provide a critical first line of defense against
reinfection [6]. Logistical constraints precluded the direct
measurement of circulating PCs in this study. However, we took
advantage of the discrete six-month dry season, a period of little to
no Pf transmission, to infer the relative contributions of SLPCs and
LLPCs to the Pf-specific IgG response based on a serum IgG half-
life of ,21 days [29]. Two weeks after acute malaria, AMA1- and
MSP1-specific Ab levels increased significantly and then decreased
over a six-month period to a point just above pre-infection levels,
indicating that the majority of PCs generated in response to acute
Pf infection were short-lived. This observation is consistent with
previous studies that described rapid declines in Pf-specific Ab
within weeks of an acute malaria episode [30,31]. We infer that
the small net increase in Pf-specific Ab at the end of the six-month
dry season represents the acquisition of Pf-specific LLPCs. Because
Pf transmission resumes after the six-month dry season, we cannot
estimate the long-term decay rate of Pf-specific Ab in the absence
of reinfection. It remains to be seen whether long-term decay rates
of Pf-specific Ab are comparable to rates of Ab decay after
exposure to common viral and vaccine antigens such as mumps
and measles, for example, which elicit Ab with half-lives exceeding
200 years [32]. The small incremental gains in AMA1- and MSP1-
specific Abs in response to acute malaria mirrors the gradual
exposure-related increase in Pf-specific MBCs, consistent with the
long-lived Abs being the products of LLPCs derived from MBCs.
Unlike the response to some other pathogens, such as measles,
which induce long-lived protective Abs after a single exposure, it
may be that repeated exposure to the Pf parasite is necessary to
‘fill’ the Pf-specific LLPC compartment to the point where basal
levels of circulating Abs to any given Pf antigen reach a protective
threshold. In a separate study of this cohort, we observed a similar
pattern of transient increases during the malaria season of Abs
specific for a large number of Pf antigens using protein
microarrays [33] suggesting that malaria induces a relatively high
SLPC-to-LLPC ratio that is not exclusively a function of the
inherent qualities of any given antigen per se.
In contrast to the highly efficient immune response to a single
smallpox vaccination, which generates long-lived (.50 years)
MBCs in nearly all vaccinees [34], a remarkably high proportion
of adults in the present study did not have detectable AMA1- or
MSP1-specific MBCs despite annual exposure to 50–60 infective
mosquito bites per person per month at the height of the malaria
season [17], similar to what Dorfman et al. observed in a cross-
sectional study in Kenya [35]. Importantly, most female adults in
the present study had detectable TT-specific MBCs three to ten
years after a single TT booster vaccine in adolescence. We
previously reported that AMA1- and MSP1-specific MBCs were
reliably generated in Pf-naı ¨ve U.S. adults following just two
vaccinations [16]. Taken together, these observations indicate that
the relatively inefficient generation and/or maintenance of Pf-
specific MBCs in response to natural Pf infection cannot be
ascribed entirely to inherent deficiencies in the antigens them-
selves. Collectively, these observations raise a central question: if
AMA1 and MSP1-specific MBCs and Abs can be efficiently
generated by vaccination of Pf-naı ¨ve adults, and TT-specific
MBCs and Abs can be efficiently generated by vaccination of Pf-
exposed individuals in this cohort, what underlies the inefficient
acquisition and/or maintenance of AMA1 and MSP1-specific
MBCs and Abs in response to natural Pf infection? One simple
answer, in addition to parasite antigenic variation [36,37], might
be that the enormous number of antigens encoded by the over
5,400 Pf genes overwhelms the immune system’s capacity to select
for and commit a sufficient number of MBCs and LLPCs specific
for any given Pf antigen to a long-lived pool [38]. If immunity to
clinical malaria requires high levels of antibodies to a large
number of Pf proteins, then the inability to commit large numbers
of MBCs and LLPCs specific for any given Pf antigen during any
given infection, as shown here, may explain, in part, why malaria
immunity is acquired slowly. In this scenario the Pf-infected
individual is capable of the normal generation and maintenance of
MBCs and LLPCs, but acquiring a sufficient number of MBCs
and LLPCs to a large number of antigens may simply take years.
It is also possible that Pf infection disrupts the immune system’s
ability to generate or maintain MBCs or LLPCs. The differenti-
ation of B cells into long-lived MBCs depends to a great extent on
the affinity of their BCRs for antigen. Recently, evidence was
presented that affinity maturation of B cells may fail to occur in the
absence of adequate Toll-like receptor (TLR) stimulation [39]. We
recently reported that Malian adults were relatively refractory to
CpG, a TLR9 agonist incorporated into two subunit malaria
vaccine candidates [40], raising the possibility that the slow
acquisition of MBCs observed here may be due to a failure of B
cells to undergo affinity maturation during Pf infection. Although
our data do not directly address the role of apoptosis in the gradual
acquisition of Pf-specific MBCs, it is worth noting that we found
no evidence of Pf-induced ablation of Plasmodium-specific MBCs, as
was observed in mice four days after Plasmodium yoelii infection
[41]. The relatively inefficient response to natural Pf infection also
does not appear to be due to a persistent, Pf-induced general
immunosuppression as the frequency of TT-specific MBCs
increased significantly in most adult females in response to a
single TT booster vaccination, an increase that appeared to be
maintained for years. In an experimental model of lymphocytic
choriomeningitis virus (LCMV) infection, a high antigen-to-B cell
ratio disrupted germinal center formation and the establishment of
B cell memory [42]. It is plausible that a similar mechanism is at
play during the blood stage of Pf infection when the immune
system encounters high concentrations of parasite proteins.
Indeed, germinal center disruption is observed in mice infected
with P. berghei ANKA [43] and P. chabaudi [44]. It is also possible
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regulation of B cell differentiation [45] or with the signals required
for sustaining LLPCs in the bone marrow [46]. It is also
conceivable that the disproportionately high level of class-switched
SLPCs we observed in response to Pf infection arises from pre-
diversified IgM
+IgD
+CD27
+ (marginal zone) B cells—analogous to
the rapid protective response against highly virulent encapsulated
bacteria that do not elicit classical T-dependent responses [47].
These and other hypotheses could be tested by applying systems
biology methods [48] and targeted ex vivo and in vitro assays
to rigorously conducted prospective studies of Pf-exposed
populations.
We previously reported that Pf exposure is associated with a
functionally and phenotypically distinct population of FCRL4
+
hypo-responsive atypical MBCs [18], similar to the ‘exhausted’
MBCs described in HIV-infected individuals [19]. In this study,
with a larger sample size, we confirmed that Pf exposure is
associated with an expansion of FCRL4
+ MBCs. The accumula-
tion of atypical MBCs could be linked to the slow acquisition of Pf-
specific MBCs, as naı ¨ve B cells in response to Pf infection could
have a propensity to differentiate into atypical rather than classical
MBCs. We also observed that the FCRL4
+ MBC population
decreased in the peripheral circulation two weeks after acute
malaria suggesting that these MBCs are directly involved in the
response to Pf infection, possibly trafficking to secondary lymphoid
tissues. Although the function of FCRL4
+ MBCs is not established,
Moir et al. [19] suggested that FCRL4
+ ‘exhausted MBCs’
contribute to the B cell deficiencies observed in HIV-infected
individuals. In contrast, Ehrhardt et al.[49], who first described
FCRL4
+ ‘tissue-like MBCs’ in lymphoid tissues associated with
epithelium, suggested that these cells may play a protective role
during infections. At present, the factors that underlie the
expansion of atypical MBCs in this study population are not
known. Genetic or environmental factors that are associated with
Pf transmission but not accounted for in this study could explain
this observation. It will be of interest to understand the origin,
antigen-specificity, and function of FCRL4
+ MBCs in the context
of Pf infection and the potential impact of these MBCs on the
ability of children to respond to malaria vaccines.
In multivariate analysis we found no correlation between the
frequency of MBCs and levels of Abs specific for AMA1 or MSP1
and malaria risk. This is not necessarily unexpected in light of
recent clinical trials that showed that vaccination with either
AMA1 or MSP1 did not confer protection [20,21]. Furthermore,
we suspect that the frequency of MBCs per se may not reliably
predict clinical immunity to malaria regardless of antigen
specificity. Malaria symptoms only occur during the blood stages
of Pf infection and can begin as early as three days after the blood
stage infection begins [50].Because the differentiation of MBCs
into PCs peaks ,6–8 days after re-exposure to antigen [10], there
may not be sufficient time for MBCs specific for Pf blood stage
antigens to differentiate into the antibody-secreting cells that
would prevent the onset of malaria symptoms. In contrast, the
longer incubation period of other pathogens allows MBCs to
differentiate into protective antibody-secreting cells before symp-
toms develop. For example, follow-up studies of hepatitis B
vaccinees have shown that protection can persist despite the
decline of hepatitis B-specific antibodies to undetectable levels
[51], presumably due to the recall response of persistent MBCs.
Thus, protection against the blood stages of malaria may depend
on achieving and maintaining a critical level of circulating
antibody that can rapidly neutralize the parasite. MBCs may
contribute to the gradual acquisition of protective immunity by
differentiating into LLPCs with each Pf infection.
Here we also provide evidence concerning the mechanism by
which MBCs and LLPCs are maintained. We observed a
modest but statistically significant increase in TT-specific
MBCs two weeks after acute malaria, in support of the
hypothesis that MBCs are renewed by polyclonal or ‘bystander’
activation [10]. The stable frequency of TT-specific MBCs with
age suggests that the small increases associated with Pf-induced
polyclonal activation are matched by the rate of loss of
senescent TT-specific MBCs. It has also been proposed that
non-specific polyclonal stimulation maintains long-lived Ab
responses by driving MBCs to differentiate into SLPCs or
LLPCs [10]. Similarly, it has been hypothesized that Plasmodium
infection generates large amounts of non-specific Ig [52]
through polyclonal B cell activation [12,13]. However, despite
the presence of TT-specific MBCs and their expansion
following Pf infection, we did not observe a concomitant
increase in TT-specific IgG. This finding is consistent with
recent human studies that demonstrate a lack of bystander IgG
production after heterologous vaccination or viral infection
[32,53]; as well as studies in mice that demonstrate PC
persistence after MBC depletion [54], and the failure of MBCs
to differentiate into PCs in vivo upon TLR4 and 9 activation
[55]. This finding does not represent an overt inability of TT-
specific MBCs to differentiate into PCs, since adult females in
this study had a sharp increase in tetanus IgG after a single
tetanus booster. It is possible that bystander MBCs specific for
antigens other than TT differentiate into PCs after Pf infection,
but based on the results of this study we hypothesize that the
preponderance of IgG produced in response to malaria is
specific for the ,2400 Pf proteins expressed during the blood-
stage of infection [56], and that increases in ‘non-specific’ IgG
reflect boosting of cross-reactive B cells [57,58]. From a basic
immunology perspective, these data support a model in which
non-specific stimuli contribute to MBC self-renewal, but not to
the maintenance of LLPCs. Studies of other Ab specificities and
isotypes before and after malaria and other infections would
test this hypothesis further. Although a recent mouse study
showed that MBCs do not proliferate in vivo after immunization
with an irrelevant antigen [59], this may reflect the difference
in requirements for MBC maintenance in mammals with
relatively short life spans.
It is of general interest to determine which parasite products are
responsible for the polyclonal activation of MBCs observed here.
Studies in vitro suggest that Pf drives polyclonal MBC activation by
the cysteine-rich interdomain regions 1a (CIDR1a) of the Pf
erythrocyte membrane protein 1 (PfEMP1) [13,60], but it is
conceivable that Pf-derived TLR agonists [61,62] or bystander T
cell help [63,64,65] also contribute to MBC proliferation in the
absence of BCR triggering [66].
Animal models have provided important insights into the
immunobiology of Plasmodium infection [67], but ultimately,
despite obvious experimental limitations, it is critical to
investigate the human immune response to Pf in longitudinal
studies since findings from animal models do not always mirror
human biology or pertain to the clinical context [68,69]. Key
challenges for future studies will be to determine the molecular
basis of the inefficient generation of MBCs and LLPCs in
response to Pf infection and to determine the longevity of these
cells in the absence of Pf transmission over longer periods of time.
Greater insight into the molecular and cellular basis of naturally-
acquired malaria immunity could open the door to strategies that
ultimately prove useful to the development of a highly effective
malaria vaccine.
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Ethics statement
The ethics committee of the Faculty of Medicine, Pharmacy, and
Odonto-Stomatology, and the institutional review board at the
National Institute of Allergy and Infectious Diseases, National Institutes
of Health approved this study (NIAID protocol number 06-I-N147).
Written, informed consent was obtained from adult participants and
from the parents or guardians of participating children.
Study site
This study was carried out in Kambila, a small (,1k m
2) rural
village with a population of 1500, located 20 km north of Bamako,
the capital of Mali. Pf transmission is seasonal and intense at this
site from July through December. The entomological inoculation
rate measured in a nearby village was approximately 50–60
infective bites per person per month in October 2000 and fell to
near zero during the dry season [17]. A detailed description of this
site and the design of the cohort study has been published
elsewhere [14].
Sampling strategy, study participants, and malaria case
definition
In May 2006, during a two-week period just prior to the malaria
season, 225 individuals aged 2–10 years and 18–25 years were
enrolled after random selection from an age-stratified census of the
entire village population. Enrollment exclusion criteria were
hemoglobin ,7 g/dL, fever $37.5uC, acute systemic illness, use
of anti-malarial or immunosuppressive medications in the past 30
days, or pregnancy. All analysis in the present study pertains to an
age-stratified subset of individuals (n=185) randomly selected
from those who had complete sets of PBMC samples over the
entire study period. From May 2006 through May 2007,
participants were instructed to report symptoms of malaria at
the village health center, staffed 24 hours per day by a study
physician. For individuals with signs or symptoms of malaria,
blood smears were examined for the presence of Pf. Patients with
positive smear results (i.e. any level of parasitemia) were treated
with a standard 3-day course of artesunate plus amodiaquine,
following the guidelines of the Mali National Malaria Control
Program. Anti-malarial drugs were provided exclusively by the
study investigators. Children with severe malaria were referred to
Kati District Hospital after an initial parenteral dose of quinine.
For research purposes, a malaria episode was defined as an axillary
temperature $37.5uC, Pf asexual parasitemia $5000 parasites/
mL, and a nonfocal physical examination by the study physician.
Severe malaria, as defined by the WHO [15], was included in this
definition. Three clinical endpoints were used to evaluate the
relationship between Pf-specific immune responses and malaria
risk: 1) whether or not malaria was experienced, 2) the incidence of
malaria, and 3) the time to the first malaria episode. Blood smears
were prepared and venous blood samples collected during the two-
week enrollment period (month 0), 14 days after the first episode of
malaria (convalescence), and during a two-week period at the end
of the six-month dry season (month 12). Hemoglobin was typed
from venous blood samples. Stool and urine were examined at
enrollment for the presence of helminth infections. Venous blood
samples from ten healthy U.S. adult blood bank donors were
analyzed as controls. Travel histories for these U.S. adults were
not available, but prior exposure to Pf is unlikely.
PBMC and plasma collection
Blood samples (8 ml for children and 16 ml for adults) were
drawn by venipuncture into sodium citrate-containing cell
preparation tubes (BD, Vacutainer CPT Tubes) and transported
20 km to the laboratory where they were processed within three
hours of collection. Plasma and PBMCs were isolated according to
the manufacturer’s instructions. Plasma was stored at 280uC.
PBMCs were frozen in fetal bovine serum (FBS) (Gibco, Grand
Island, NY) containing 7.5% dimethyl sulfoxide (DMSO; Sigma-
Aldrich, St. Louis, MO), kept at 280uC for 24 hours, and then
stored at 2196uC in liquid nitrogen. For each individual, PBMC
and plasma samples from all time points were thawed and assayed
simultaneously.
Measurement of peripheral blood Pf parasitemia
Thick blood smears were stained with Giemsa and counted
against 300 leukocytes. Pf densities were recorded as the number
of asexual parasites/ml of whole blood, based on an average
leukocyte count of 7500/ml. Each smear was evaluated separately
by two expert microscopists blinded to the clinical status of study
participants. Any discrepancies were resolved by a third expert
microscopist.
Hemoglobin typing
Hemoglobin was typed by high performance liquid chromatog-
raphy (HPLC; D-10 instrument; Bio-Rad, Hercules, CA) as
previously described [14].
Stool and urine exam for helminth infection
At enrollment, duplicate stool samples were examined for
Schistosoma mansoni eggs and other intestinal helminths using the
semi-quantitative Kato-Katz method. To detect Schistosoma
haematobium eggs, 10 ml of urine were poured over Whatman
filter paper. One or two drops of ninhydrine were placed on the
filter and left to air dry. After drying, the filter was dampened with
tap water and helminths were eggs detected by microscopy.
Geographic information system data collection
Latitude and longitude coordinates of study subjects’ households
were measured by a handheld global positioning system receiver
(GeoXM; Trimble) and reported earlier [14].
Antibody detection by ELISA
ELISAs were performed by a standardized method as described
previously [70]. For both AMA1 and MSP1, a 1:1 mixture of FVO
and 3D7 AMA1 and MSP1 isotypes was used to coat the ELISA
plates. The limit of detection for the AMA1 and MSP1 ELISA is
based on the range of values that gives reproducible results at the
Malaria Vaccine and Development Branch at NIAID where the
assay is routinely performed. More specifically, the limit of
detection is the ELISA unit value at the lowest point on the
standard curve, multiplied by the dilution factor at which samples
are tested. The minimal detection levels for the MSP1 and AMA1
ELISA assays were 11 and 33 ELISA units, respectively. For
analysis, all data below the minimum detection level were assigned
a value of one half the limit of detection (i.e. 6 units for MSP1, 17
units for AMA1). The limit of detection for the TT ELISA was not
determined because we did not have access to TT-naı ¨ve serum.
Memory B cell analysis
Antigen-specific MBCs were quantified by a modified version of
the method developed by Crotty et al [71]. We found that adding
IL-10 to the cocktail of polyclonal activators resulted in a six-fold
increase in the efficiency of the assay (Weiss et al., unpublished
observation). Briefly, PBMCs were thawed and cultured in 24 well
plates at 37uC in a 5% CO2 atmosphere for six days in media
Memory B Cell Response to P. falciparum Malaria
PLoS Pathogens | www.plospathogens.org 10 May 2010 | Volume 6 | Issue 5 | e1000912alone (RPMI 1640 with L-Glutamine, Penicillin/Streptomycin
100 IU/ml, 10% heat-inactivated FBS, 50 mM b-Mercaptoetha-
nol) or media plus a cocktail of polyclonal activators: 2.5 mg/ml of
CpG oligonucleotide ODN-2006 (Eurofins MWG/Operon,
Huntsville, AL), Protein A from Staphylococcus aureus Cowan
(SAC) at a 1/10,000 dilution (Sigma-Aldrich, St. Louis, MO),
pokeweed mitogen at a 1/100,000 dilution (Sigma-Aldrich), and
IL-10 at 25 ng/ml (BD Biosciences). Cells were washed and
distributed on 96-well ELISPOT plates (Millipore Multiscreen
HTS IP Sterile plate 0.45 um, hydrophobic, high-protein binding)
to detect antibody-secreting cells (ASCs). ELISPOT plates were
prepared by coating with either: a 10 mg/ml solution of polyclonal
goat antibodies specific for human IgG (Caltag) to detect all IgG-
secreting cells; a 1% solution of bovine serum albumin (BSA) as a
non-specific protein control; or 5 mg/ml solutions of either tetanus
toxoid (TT), AMA1, or MSP1 to detect antigen-specific ASCs. For
AMA1 and MSP1, a 1:1 mixture of FVO and 3D7 isotypes was
used to coat the ELISPOT plates. Plates were blocked by
incubation with a solution of 1% BSA. For the detection of
antigen-specific ASCs, cells were plated in duplicate in eight serial
dilutions beginning with 5610
5 cells/well. For detection of total
IgG ASCs cells were plated at six serial dilutions beginning at
4610
4 cells/well. After a five hour incubation of the cells in the
ELISPOT plates, plates were washed four times each in PBS and
PBS-Tween 20 0.05% (PBST), and incubated overnight with a
1:1000 dilution of alkaline phosphatase-conjugated goat antibodies
specific for human IgG (Zymed) in PBST/1% FCS. Plates were
washed four times each in PBST, PBS, and ddH2O; developed
using 100 ml/well BCIP/NBT for 10 minutes; washed thoroughly
with ddH2O and dried in the dark. ELISPOTS were quantified
using Cellular Technologies LTD plate-reader and results
analyzed using Cellspot software. Results are reported as
frequencies of MBCs per 10
6 PBMCs after the six-day culture.
The limit of detection of the MBC ELISPOT assay for this
analysis was five ASCs per 10
6 PBMC based on the average
number of ASCs on the BSA control. Assay failure was defined as
fewer than 1000 IgG
+ ASCs per 10
6 PBMCs after the six-day
culture which resulted in the exclusion of 15% of individuals at
month 0, 13.2% 14 days after the first malaria episode, and 7.3%
at month 12. For individuals with a limited number of PBMCs,
priority was given to performing the ELISPOT assay for MSP1,
then TT, and then AMA1.
Phenotypic analysis of B cell subsets
All phenotypic analyses were performed using mouse mAbs
specific for human B cell markers conjugated to fluorophores as
previously reported [18]. Fluorophore-conjugated mAbs specific
for the following markers were used: PECy7-CD19, PE-CD20,
APC-CD10, APC-CD27, PE-IgG (BD Biosciences, San Jose, CA)
and FITC-CD21 (Beckman Coulter, Fullerton, CA). A four-color,
two-stain strategy was used to identify B cell subsets as follows:
plasma cells/blasts (CD19
+ CD21
2 CD20
2), naive B cells (CD19
+
CD27
2CD10
2), immature B cells (CD19
+ CD10
+), classical
MBCs (CD19
+ CD27
+ CD21
+), atypical MBCs (CD19
+ CD21
2
CD27
2 CD10
2) and activated MBCs (CD19
+ CD21
2
CD27
+CD20
+). FACS analyses were performed on a FACSCa-
libur flow cytometer (BD Biosciences) using FlowJo software (Tree
Star, Ashland, OR).
Statistical analysis
Data were analyzed using STATA (StataCorp LP, Release 10.0)
and GraphPad Prism for Windows (GraphPad Software, version
5.01).The Kruskal-Wallis test was used to compare continuous
variables between groups, and the Fisher’s exact test was used to
compare categorical variables. The Wilcoxon matched-pairs
signed-rank test was used to compare measurements of the same
parameter at two time points for the same individual. The
correlation between different continuous measures was determined
by using the Spearman correlation coefficient. The malaria-free
probability over the twelve-month study period was estimated by
the Kaplan-Meier curve, and the time to the first malaria episode
was compared by the log rank test. Cox’s proportional hazards
model was used to assess the effect of the following factors on the
hazard of malaria: age, gender, weight, ethnicity, distance lived
from study clinic, self-reported bednet use, hemoglobin type,
antigen-specific MBC frequencies and Ab levels. The same list of
variables was included in logistic and Poisson regression models to
determine their impact on the odds and incidence of malaria
episodes, respectively. For all tests, two-tailed p values were
considered significant if #0.05.
Supporting Information
Figure S1 Correlative analysis of antibody levels and memory B
cell frequencies specific for AMA1, MSP1, and tetanus toxoid.
Shown are scatterplots of antibody levels versus memory B cell
frequencies specific for (A) AMA1 (n=64), (B) MSP1 (n=67) and
(C) tetanus toxoid (n=128). Data are derived from venous blood
samples drawn before the malaria season. Only individuals with
both antibody and memory B cell data are included. For AMA1
and MSP1 the plots include individuals with antibody levels at or
above the limit of detection of the ELISA. Individuals with ‘failed’
ELISPOT assays are not included. As described in ‘Materials and
Methods’, assay failure was defined as fewer than 1000 IgG
+ ASCs
per 10
6 PBMCs after the six-day culture. The Spearman’s
correlation coefficient is given for each plot.
Found at: doi:10.1371/journal.ppat.1000912.s001 (3.84 MB TIF)
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